Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines and arylthioalkylamines, including pyridyloxylalkylamines, phenoxyalkylamines, pyridylthiolalkylamines and phenylthioalkylamines. Exemplary compounds include (2-(5-bromo(3-pyridylthio))ethyl)methylamine, (2-(5-bromo(3-pyridylthio))isopropyl)methylamine, (2-(5-bromo(3-pyridylthio))propyl)methylamine, (3-(5-bromo(3-pyridylthio))propyl)methylamine, 3-((3S)-3-pyrrolidinyloxy)pyridine, 3-(4-piperidinyloxy)pyridine, 3-(1-methyl-4-piperidinyloxy)pyridine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, and methyl(3-tricyclo[7.3.1.0<5,13>]tridec-2-yloxypropyl)amine.
对于容易受到或患有中枢神经系统疾病等疾病和疾患的患者,可以通过给予需要的患者芳氧烷胺和芳
硫烷胺来进行治疗,包括
吡啶氧烷胺、苯氧基胺、
吡啶硫胺和苯
硫胺。示例化合物包括(2-(5-
溴(3-
吡啶硫))乙基)
甲胺,(2-(5-
溴(3-
吡啶硫))异丙基)
甲胺,(2-(5-
溴(3-
吡啶硫))丙基)
甲胺,(3-(5-
溴(3-
吡啶硫))丙基)
甲胺,3-((3S)-3-
吡啶氧)
吡啶,3-(4-
哌啶氧)
吡啶,3-(1-甲基-4-
哌啶氧)
吡啶,(3-苯并[3,4-d]1,3-二氧杂环戊-5-氧丙基)
甲胺和甲基(3-
三环[7.3.1.0<5,13>]
十三烷-2-氧丙基)胺。